Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialShukui Qin, Yabing Guo, Lu Wang et al.|The Lancet|2023Cited by 514
Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic RoleStefania De Lorenzo, Giovanni Brandi, Francesco Tovoli et al.|Cancers|2020Cited by 56
Safety and Efficacy of 6-thioguanine as a Second-line Treatment for Autoimmune HepatitisClémence Legué, Edouard Bardou‐Jacquet, Ludivine Legros et al.|Clinical Gastroenterology and Hepatology|2017Cited by 24
Impact of HCV treatment on long term mortality in patients >= 70 years at the time of HCV infection diagnosisClémence Legué, Dominique Guyader, Charlotte Pronier et al.|Unknown|2017Cited by 0